EU approves Sanofi-GSK booster COVID jab

Thursday, 10. November 2022 17:51

The European Medicines Agency's (EMA) medicines committee recommended on Thursday the authorization of the COVID-19 vaccine jointly developed by Sanofi SA and GSK plc as a booster dose in the adult population.

The inactivated vaccine VidPrevtyn Beta, approved by the European Commission, is equally effective in protecting against COVID-19 as the vaccine from Pfizer and BioNTech.

Commenting on the recommendation, executives at Sanofi and GSK noted that the batch of VidPrevtyn Beta jabs is ready for the EU's winter vaccination campaign.

Sanofi's shares stood slightly in the green territory at today's closing bell in Paris following the news, selling for €86.97 apiece after rebounding in late October to levels last seen in mid-August. Meanwhile, GSK's stock gained 2.5% at 5:55 pm CET to sell for $33.27 at IEX.

Related Links: GlaxoSmithKline PLCSanofi S.A.
Baha Breaking News (BBN) / ND